NEW YORK (GenomeWeb) – RiboMed Biotechnologies and Tocagen today announced a collaboration to use RiboMed's technology to analyze potential epigenetic prognostic and predictive markers in Tocagen's clinical trials evaluating the investigational treatment Toca 511 and Toca FC in patients with recurrent high grade gliomas (HGGs).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.